Sunday, October 31, 2021



Eris Lifesciences Q2 PAT up 9.91% at Rs118.39cr on stable sales growth and stable operating margins

Eris Lifesciences Ltd reported 8.99% growth in total revenues for the Sep-21 quarter on consolidated basis at Rs359.67cr

Eris Lifesciences Ltd reported 8.99% growth in total revenues for the Sep-21 quarter on consolidated basis at Rs359.67cr. The revenues were higher by 2.98% on a sequential basis compared to Rs349.27cr revenues in the Jun-21 quarter.

For the first half of the fiscal year FY22 ended September 2021, Eris Lifesciences reported a 13.8% growth in top line revenues at Rs709cr. The company operates in a niche where margins have been relatively stable.

The consolidated Profit after tax (PAT) for the Sep-21 quarter was up 9.91% at Rs118.39cr on the back of largely stable operating margins over time. Even the raw material costs have been relatively stable over time despite the supply chain constraints quite rampant across the sector. Other expenses were around 10% higher on a yoy basis.

The PAT was higher by 11% sequentially. Net margins at 32.92% was marginally higher than 32.64% on a yoy basis in Sep-20 quarter and better compared to NPM of 30.54% in Jun-21 quarter.


Consistence performer , Good long term and short term outlook . 750- 762 is strong support zone. Buy on dips.

Disclaimer- The information on this blog are based on my personal opinion and experience, it should not be considered professional financial investment advice and in no way it should be considered as a tip. We does not take any compensation of any kind whatsoever from any reader, user and company that are mention on this website. We are not SEBI registered financial advisor or analyst.

No comments:

Post a Comment